ReviewCurrent opinion in hematology2010
Emerging therapeutic approaches for multipotent mesenchymal stromal cells.
Review in Current opinion in hematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?Blood reviews · 2021Review
- Preclinical translation of exosomes derived from mesenchymal stem/stromal cells.Stem cells (Dayton, Ohio) · 2020Review
- [The Use Of Pulmonary Gene Therapy In The Treatment Of Experimental Models Of Pneumonia And Septicemia].Gaceta medica de Caracas · 2018Article
- Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine.Stem cells translational medicine · 2017Review
- Mesenchymal Stem Cell Soluble Mediators and Cystic Fibrosis.Journal of stem cell research & therapy · 2017Article
- Comparative Clinical Observation of Arthroscopic Microfracture in the Presence and Absence of a Stromal Vascular Fraction Injection for Osteoarthritis.Stem cells translational medicine · 2017Article
- Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging.Frontiers in oncology · 2017Review
- A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance.Stem cell research & therapy · 2015Article
- MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ production.American journal of hematology · 2015Article
- Immunosuppressive properties of Wharton's jelly-derived mesenchymal stromal cells in vitro.International journal of hematology · 2015Article
- Single cell-derived clones from human adipose stem cells present different immunomodulatory properties.Clinical and experimental immunology · 2014Article
- Immunomodulatory nature and site specific affinity of mesenchymal stem cells: a hope in cell therapy.Advanced pharmaceutical bulletin · 2014Review
- Transplantation of Nonexpanded Adipose Stromal Vascular Fraction and Platelet-Rich Plasma for Articular Cartilage Injury Treatment in Mice Model.Journal of medical engineering · 2013Article
- Enhanced healing of diabetic wounds by subcutaneous administration of human umbilical cord derived stem cells and their conditioned media.International journal of endocrinology · 2013Article
- Mesenchymal stem cells in mammary adipose tissue stimulate progression of breast cancer resembling the basal-type.Cancer biology & therapy · 2012Article
- The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.Immunotherapy · 2012Review
- Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety.International archives of medicine · 2012Article
- Cell therapy for multiple sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2011Review
- Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds.Annual review of biomedical engineering · 2011Review
- Selecting the optimal cell for kidney regeneration: fetal, adult or reprogrammed stem cells.OrganogenesisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewMultipotent mesenchymal stromal cells (MSCs) are rare cells resident in bone marrow and other organs capable of differentiating into mesodermal lineage tissues. MSCs possess immunomodulatory properties and have extensive capacity for ex-vivo expansion. Early clinical studies demonstrated safety and feasibility of infusing autologous MSCs and suggested a role in enhancing engraftment after hematopoietic cell transplant (HCT). Subsequent pilot studies using allogeneic MSCs showed safety but presented contradictory results regarding efficacy in treating graft-versus-host disease (GVHD). RECENT
findingsLarger, phase II allogeneic MSC infusion studies, including cells obtained from haploidentical and third-party donors, showed efficacy in GVHD treatment; however, recent randomized, placebo-controlled studies failed to corroborate these results. New investigations include MSC infusions in umbilical cord blood transplantation, MSC therapy for tissue regeneration/repair, harvest and use of MSCs from adipose tissue and cell-tracking/imaging studies using radionuclides, gene and fluorescent dye-labeled MSCs. SUMMARY: MSCs remain the subject of intense investigation in HCT because of their differentiation potential and immunomodulatory properties. Whereas infusions of autologous, allogeneic and third-party donor MSCs are well tolerated, further research is needed to clarify the optimal methods for harvesting and expansion, optimal timing of administration and efficacy in the setting of HCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.